Pharmacogenomics

---

Costs and quality of genomics tests in the oncology field

WCRJ 2016; 3 (4): e801

A cost-effectiveness method for detection of ABL mutations in patients who developed Imatinib resistance

WCRJ 2016; 3 (4): e799

Evaluation of clinical and economic impact of pharmacogenomics testing in taxanes-based therapy

WCRJ 2016; 3 (3): e744

Pharmacogenomics of Cytochrome P450 Family enzymes: implications for drug-drug interaction in anticancer therapy

WCRJ 2015; 2 (1): e483

Rational selection of PCR-based platforms for pharmacogenomic testing

WCRJ 2014; 1 (4): e391

Pharmacogenetic based drug-drug interactions between Highly Active Antiretroviral Therapy (HAART) and antiblastic chemotherapy

WCRJ 2014; 1 (4): e386

Comparing methods for isolation of circulating-DNA (C-DNA). Implication of C-DNA as biomarker in the cancer

WCRJ 2014; 1 (4): e384

Pharmacogenomics of Gemcitabine in the tailor-made therapy

WCRJ 2014; 1 (4): e360

Impact of DPYD variants in Fluoropyrimidine based-therapy: the state of the art

WCRJ 2014; 1 (3): e279

Pharmacogenomics markers for prediction response and toxicity in cancer therapy

WCRJ 2014; 1 (3): e276

• 1
• 2
• Older